ES2196194T3 - Igf-i y -ii destinados al tratamiento de enfermedades del sistema nervioso central. - Google Patents

Igf-i y -ii destinados al tratamiento de enfermedades del sistema nervioso central.

Info

Publication number
ES2196194T3
ES2196194T3 ES96942947T ES96942947T ES2196194T3 ES 2196194 T3 ES2196194 T3 ES 2196194T3 ES 96942947 T ES96942947 T ES 96942947T ES 96942947 T ES96942947 T ES 96942947T ES 2196194 T3 ES2196194 T3 ES 2196194T3
Authority
ES
Spain
Prior art keywords
igf
diseases
nervous system
central nervous
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96942947T
Other languages
English (en)
Inventor
Douglas N Ishii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AUROGEN Inc
Original Assignee
AUROGEN Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AUROGEN Inc filed Critical AUROGEN Inc
Application granted granted Critical
Publication of ES2196194T3 publication Critical patent/ES2196194T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION TRATA DE UN PROCEDIMIENTO PARA LLEVAR A CABO CAMBIOS EN EL SISTEMA NERVIOSO CENTRAL, INCLUYENDO EL TRATAMIENTO DE LOS TRASTORNOS O ENFERMEDADES DEL CEREBRO Y DE LA ESPINAL DORSAL, MEDIANTE LA ADMINISTRACION PARENTERAL DE FACTORES DEL CRECIMIENTO DEL TIPO DE LA INSULINA I (IGF - I) O DEL FACTOR DEL CRECIMIENTO DEL TIPO DE LA INSULINA II (IGF - II).
ES96942947T 1995-12-13 1996-12-11 Igf-i y -ii destinados al tratamiento de enfermedades del sistema nervioso central. Expired - Lifetime ES2196194T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57180295A 1995-12-13 1995-12-13

Publications (1)

Publication Number Publication Date
ES2196194T3 true ES2196194T3 (es) 2003-12-16

Family

ID=24285123

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96942947T Expired - Lifetime ES2196194T3 (es) 1995-12-13 1996-12-11 Igf-i y -ii destinados al tratamiento de enfermedades del sistema nervioso central.

Country Status (7)

Country Link
EP (1) EP0874641B1 (es)
JP (1) JP2000514038A (es)
AT (1) ATE236652T1 (es)
CA (1) CA2240327C (es)
DE (1) DE69627379T2 (es)
ES (1) ES2196194T3 (es)
WO (1) WO1997021449A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003262552A1 (en) * 2003-07-29 2005-02-25 Ares Trading S.A. Use of human growth hormone in multiple system atrophy
ES2322685B2 (es) * 2006-11-21 2010-03-15 Universidad De Malaga Utilizacion de dosis bajas de igf-ii en el envejecimiento por sus efectos neuroprotectores y hepatoprotectores.
US20140286906A1 (en) * 2011-10-06 2014-09-25 Daniel Bilbao Cortes Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases
ES2927133B2 (es) * 2021-04-28 2023-12-29 Univ Malaga Tratamiento para la enfermedad de Parkinson

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
DE69218948T2 (de) * 1991-08-01 1997-07-31 Genentech Inc IGF-I zur Verbesserung der neuronale Lage
US5733871A (en) * 1991-11-08 1998-03-31 The General Hospital Corporation Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
CA2176708A1 (en) * 1993-11-15 1995-05-26 Christopher A. Maack Method of treating neurological disorders

Also Published As

Publication number Publication date
EP0874641B1 (en) 2003-04-09
DE69627379T2 (de) 2004-02-05
DE69627379D1 (de) 2003-05-15
CA2240327C (en) 2005-07-12
JP2000514038A (ja) 2000-10-24
WO1997021449A1 (en) 1997-06-19
CA2240327A1 (en) 1997-06-19
EP0874641A1 (en) 1998-11-04
ATE236652T1 (de) 2003-04-15

Similar Documents

Publication Publication Date Title
ATE459335T1 (de) Verfahren zur behandlung von augenerkrankungen
EP0476044A4 (en) Treating disorders by application of insulin-like growth factors and analogs
IL148071A0 (en) Method for treatment of symptoms of central nervous system disorders
AU2746897A (en) Techniques for treating epilepsy by brain stimulation and drug infusion
ATE239493T1 (de) Anwendung von hgf zur herstellung eines medikaments gegen zentralnervensystemstörungen
WO2004037204A3 (en) Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
FR12C0004I1 (es)
AU2674797A (en) Method of treating movement disorders by brain infusion
WO2004036370A3 (en) Channel-selective blanking for a medical device system
EP0651650A4 (en) METHOD FOR TREATING EYE DISEASES BY MEANS OF TGF - g (b).
WO2003030823A3 (en) Combinations for the treatment of immunoinflammatory disorders
ATE178801T1 (de) Tgf-beta zur verbesserung der regeneration von neuronalem gewebe
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
TR200102864T2 (tr) N”rolojik ya da n”ropsikiyatrik bozukluklarìn tedavisi i‡in y”ntem
AUPR220300A0 (en) New epilepsy gene
ES2196194T3 (es) Igf-i y -ii destinados al tratamiento de enfermedades del sistema nervioso central.
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
IL117157A0 (en) Preparation of factor ix from biological sources
UA29437C2 (uk) (s)-альфа-феніл-2-піридинетанамін або його сіль з неорганічною кислотою, які мають протисудомну активність, спосіб їх отримання, лікарський препарат на їх основі та спосіб лікування судом
EP0495998A4 (es)
ATE320263T1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
MY116362A (en) Use of selegiline for the treatment of epileptic disorders
UA10235A (uk) Спосіб корекції дезадаптаційних розладів організму
UA30749A (uk) Спосіб комплексної стимулотерапії тяжких форм мовних розладів
UA10259A (uk) Протинабряковий лікарський препарат "нейрополіосм"